Clinical and laboratory characteristics of patients with severe COVID-19 undergoing gene engineering therapy
- Authors: Rogozhkina A.V.1, Pogromskaya M.N.1,2, Romanova E.S.1,2, Startseva G.Y.1,2, Filipovich O.M.1,2, Klur M.V.1, Antonov V.M.1
-
Affiliations:
- North-Western State Medical University named after I.I. Mechnikov
- Clinical Infectious Diseases Hospital named after S.P. Botkin
- Issue: Vol 28, No 4 (2024)
- Pages: 62-71
- Section: Original study article
- URL: https://journals.rcsi.science/RFD/article/view/280660
- DOI: https://doi.org/10.17816/RFD635932
- ID: 280660
Cite item
Abstract
Background: One of the primary factors contributing to an increased risk of fatal outcomes in severe COVID-19 cases is the development of a cytokine storm, a hyperimmune response characterized by excessive cytokine release. Despite using biologic therapies, mortality rates in severe COVID-19 cases remain significantly high.
Aim: To analyze and evaluate the clinical and laboratory parameters of patients with severe COVID-19 who received biologic therapy.
Materials and methods: A cluster sampling method was employed, with clusters selected based on the severity of the primary disease and biologic therapy. The study included 65 patients, divided into two groups based on disease outcomes: Group 1 comprised 34 patients with favorable outcomes, while Group 2 included 31 patients with fatal outcomes.
Results: Significant differences were observed between the groups in terms of age (p = 0.01). Patients in Group 2 (with fatal outcomes) had a higher burden of co-morbidities, as measured by the Charlson Comorbidity Index (p = 0.00009) and the Cumulative Illness Rating Scale for Geriatrics (CIRS-G; p = 0.000003). Additionally, the groups differed significantly in the number of days from disease onset to the initiation of biologic therapy (p = 0.02). In Group 2, delayed initiation of biologic therapy was associated with persistently high concentrations of acute-phase proteins.
Conclusions: Key factors influencing the efficacy of biologic therapy for severe COVID-19 with cytokine storm include patient age, the presence and severity of co-morbidities, and the timing of hospitalization and initiation of biologic therapy.
Full Text
##article.viewOnOriginalSite##About the authors
Aleksandra V. Rogozhkina
North-Western State Medical University named after I.I. Mechnikov
Author for correspondence.
Email: gostevaaleksandra@gmail.com
ORCID iD: 0000-0003-4423-7408
SPIN-code: 4984-6618
MD
Russian Federation, 41 Kirochnaya St., Saint Petersburg, 191015Margarita N. Pogromskaya
North-Western State Medical University named after I.I. Mechnikov; Clinical Infectious Diseases Hospital named after S.P. Botkin
Email: M.Pogromskaya@szgmu.ru
ORCID iD: 0000-0001-8072-6589
MD, Cand. Sci. (Medicine), Assistant Professor
Russian Federation, 41 Kirochnaya St., Saint Petersburg, 191015; Saint PetersburgElena S. Romanova
North-Western State Medical University named after I.I. Mechnikov; Clinical Infectious Diseases Hospital named after S.P. Botkin
Email: E.Romanova@szgmu.ru
ORCID iD: 0000-0002-9887-8561
SPIN-code: 9435-6838
MD, Cand. Sci. (Medicine), Assistant Professor
Russian Federation, 41 Kirochnaya St., Saint Petersburg, 191015; Saint PetersburgGalina Yu. Startseva
North-Western State Medical University named after I.I. Mechnikov; Clinical Infectious Diseases Hospital named after S.P. Botkin
Email: star661@rambler.ru
ORCID iD: 0000-0002-3660-2666
SPIN-code: 8392-2950
MD, Cand. Sci. (Medicine), Assistant Professor
Russian Federation, 41 Kirochnaya St., Saint Petersburg, 191015; Saint PetersburgOlga M. Filipovich
North-Western State Medical University named after I.I. Mechnikov; Clinical Infectious Diseases Hospital named after S.P. Botkin
Email: filipowitch.olga@yandex.ru
ORCID iD: 0000-0001-9569-6941
SPIN-code: 3667-8214
MD
Russian Federation, 41 Kirochnaya St., Saint Petersburg, 191015; Saint PetersburgMargarita V. Klur
North-Western State Medical University named after I.I. Mechnikov
Email: rita-med@mail.ru
ORCID iD: 0009-0006-6222-2452
MD, Cand. Sci. (Medicine), Assistant Professor
Russian Federation, 41 Kirochnaya St., Saint Petersburg, 191015Vsevolod M. Antonov
North-Western State Medical University named after I.I. Mechnikov
Email: Vsevolod.Antonov@szgmu.ru
ORCID iD: 0009-0002-3172-7926
SPIN-code: 9925-2139
MD, Cand. Sci. (Medicine), Assistant Professor
Russian Federation, 41 Kirochnaya St., Saint Petersburg, 191015References
- Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–1242. doi: 10.1001/jama.2020.2648
- Shherbak SG, Kamilova TA, Golota AS, Vologzhanin DA. Risk factors for severe course and lethal outcome of COVID-19. Physical and Rehabilitation Medicine, Medical Rehabilitation. 2022;4(1):14–36. EDN: IWIVWC doi: 10.36425/rehab104997
- Potapnev MP. Cytokine storm: causes and consequences. Immunologiya. 2021;42(2):175–188. EDN: KTUDQQ doi: 10.33029/0206-4952-2021-42-2-175-188
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5
- Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46:1294–1297. doi: 10.1007/s00134-020-05991-x
- Morris G, Bortolasci C, Puri BK, et al. Preventing the development of severe COVID-19 by modifying immunothrombosis. Life Sci. 2021;264:118617. doi: 10.1016/j.lfs.2020.118617
- Jayarangaiah A, Kariyanna PT, Chen X, et al. COVID-19-associated coagulopathy: an exacerbated immunothrombosis response. Clin Appl Thromb Hemost. 2020;26:1–11. doi: 10.1177/1076029620943293
- Chernyh ER, Leplina OJu, Tihonova MA, et al. Cytokine balance in the pathogenesis of systemic inflammatory response: a new target for immunotherapeutic interventions in the treatment of sepsis. Medical Immunology. 2001;3(3):415–429. (In Russ.). EDN: JUARZX
- Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020;27(5):1451−1454. doi: 10.1038/s41418-020-0530-3
- Nguyen A, David JK, Maden SK, et al. Human leukocyte antigen susceptibility map for SARS-CoV-2. J Virol. 2020;94(13):1−12. doi: 10.1128/JVI.00510-20
- Williamson E, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–436. doi: 10.1038/s41586-020-2521-4
- Zhang J, Wang X, Jia X, et al. Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. Clin Microbiol Infect. 2020;26(6):767−772. doi: 10.1016/j.cmi.2020.04.012
- Vorob’eva NA, Vorob’eva AI. Predictive value of D-dimer in COVID -19. Health care Standardization Problems. 2021;5(6):36−42. EDN: AYAAXX doi: 10.26347/1607-2502202105-06036-042
- Ponti G, Maccaferri M, Ruini C, et al. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020;57(6):389−399. doi: 10.1080/10408363.2020.1770685
- Ishikawa T. Clinical preparedness for cytokine storm induced by the highly pathogenic H5N1 influenza virus. J Pharmacogenom Pharmacoproteomics. 2012;3(6):1000e131. doi: 10.4172/2153-0645.1000e131
- Polushin JuS, Shlyk IV, Gavrilova EG, et al. The role of ferritin in assessing COVID-19 severity. Bulletin of anesthesiology and resuscitation. 2021;18(4):20−28. EDN: VGUGSZ doi: 10.21292/2078-5658-2021-18-4-20-28
- Kuznecov IA, Potievskaja VI, Kachanov IV, Kuraleva OO. Ferritin’s role in biological circles of the person. Modern problems of science and education. 2017;(5):206. EDN: ZQNIGV
- Antoshkin ON, Vorotnikova TV. Analysis of complications from coronavirus infection COVID-19 according to pathoanatomical studies. Journal of Volgograd state medical university. 2021;78(2):156−159. EDN: FTGALT doi: 10.19163/1994-9480-2021-2(78)-156-159
Supplementary files
